bristol myerd squibb cowen and company health care conference
Post on 27-Jul-2015
917 Views
Preview:
TRANSCRIPT
1This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Research & DevelopmentResearch & DevelopmentUpdateUpdate
Brian Daniels, MDBrian Daniels, MDSenior Vice President,Senior Vice President,Global DevelopmentGlobal Development
Cowen Healthcare ConferenceMarch 17, 2008
2This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
During this meeting, we will make statements about the CompanyDuring this meeting, we will make statements about the Company’’s future s future plans and prospects, including statements about our financial poplans and prospects, including statements about our financial position, sition, business strategy, research pipeline concerning product developmbusiness strategy, research pipeline concerning product development and ent and product potential, that constitute forwardproduct potential, that constitute forward--looking statements for purposes looking statements for purposes of the safe harbor provisions under the Private Securities Litigof the safe harbor provisions under the Private Securities Litigation Reform ation Reform Act of 1995.Act of 1995.
Actual results may differ materially from those indicated by theActual results may differ materially from those indicated by these forwardse forward--looking statements as a result of various important factors, inclooking statements as a result of various important factors, including those luding those discussed in the companydiscussed in the company’’s most recent annual report on Form 10s most recent annual report on Form 10--K, K, periodic reports on Form 10periodic reports on Form 10--Q and current reports on Form 8Q and current reports on Form 8--K. These K. These documents are available from the SEC, the Bristoldocuments are available from the SEC, the Bristol--Myers Squibb websiteMyers Squibb websiteor from Bristolor from Bristol--Myers Squibb Investor Relations.Myers Squibb Investor Relations.
In addition, any forwardIn addition, any forward--looking statements represent our estimates only as looking statements represent our estimates only as of today and should not be relied upon as representing our estimof today and should not be relied upon as representing our estimates as of ates as of any subsequent date. While we may elect to update forwardany subsequent date. While we may elect to update forward--looking looking statements at some point in the future, we specifically disclaimstatements at some point in the future, we specifically disclaim any any obligation to do so, even if our estimates change.obligation to do so, even if our estimates change.
3This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Track Record of Success: Nine New Track Record of Success: Nine New Drug Approvals in Less Than Five YearsDrug Approvals in Less Than Five Years
20042004 20052005 20062006 20072007
Otsuka AmericaPharmaceutical, Inc.
ImClone SystemsIncorporated
HIV / AIDS
Schizophrenia, Depression
Cancer
Hepatitis B
Rheumatoid ArthritisHIV / AIDS
Cancer
Cancer
Depression
SomersetPHARMACEUTICALS INC.
20032003
4This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Next Generation Next Generation BioPharmaBioPharma ModelModel
Next GenerationBioPharma
Best of PharmaBest of Biotech
Innovative Innovative PortfolioPortfolio
Selectively Selectively Integrated Integrated
Business ModelBusiness ModelContinuous Continuous
ImprovementImprovement
Agile, Entrepreneurial and Accountable Culture
5This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Therapeutic Therapeutic AreaArea Disease AreaDisease Area Unmet Medical NeedUnmet Medical Need
Athero/ThrombosisAthero/Thrombosis •• Improved therapeutic windowImproved therapeutic window
DiabetesDiabetes •• Prevention of complicationsPrevention of complications•• Slowing or halting of disease progressionSlowing or halting of disease progression
CardioCardio--vascularvascularandandMetabolicsMetabolics ObesityObesity •• Increased efficacy and high degree of safety Increased efficacy and high degree of safety
HIVHIV •• Overcoming resistanceOvercoming resistanceVirologyVirology
OncologyOncology
NeuroscienceNeuroscience
ImmunologyImmunology
HepatitisHepatitis •• Targeted Targeted antiviralsantivirals that improve cure ratesthat improve cure rates•• Overcoming resistanceOvercoming resistance
OncologyOncology •• Increasing survivalIncreasing survival •• Less toxicityLess toxicity•• Improved quality of lifeImproved quality of life •• Personalized therapyPersonalized therapy
Psychiatric DisordersPsychiatric Disorders•• Onset of action Onset of action •• Improved efficacy and Improved efficacy and
tolerabilitytolerability•• Enhanced complianceEnhanced compliance
AlzheimerAlzheimer’’ss •• Delay disease onsetDelay disease onset •• Disease modificationDisease modification•• Better symptom reliefBetter symptom relief
RA and Related RA and Related DiseasesDiseases
•• Oral agentsOral agents •• Disease modificationDisease modification•• Improved tolerability and safetyImproved tolerability and safety
Solid Organ TransplantSolid Organ Transplant •• Increased longIncreased long--term efficacy with improved safetyterm efficacy with improved safety
BMS Disease Areas and Unmet Medical NeedBMS Disease Areas and Unmet Medical Need
6This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Development PortfolioDevelopment PortfolioFull Development(Registrational, Filed)
•• IxempraIxempra ((IxabepiloneIxabepilone) ) (Cancer)(Cancer)
•• IpilimumabIpilimumab(Cancer)(Cancer)
•• BelataceptBelatacept(Solid Organ Transplant)(Solid Organ Transplant)
•• SaxagliptinSaxagliptin(Diabetes)(Diabetes)
•• DapagliflozinDapagliflozin(Diabetes)(Diabetes)
•• ApixabanApixaban(Thrombosis)(Thrombosis)
Life Cycle Management
•• Sprycel Sprycel (Cancer) (Cancer)
•• Erbitux Erbitux (Cancer)(Cancer)
•• OrenciaOrencia(Rheumatoid Arthritis)(Rheumatoid Arthritis)
•• PlavixPlavix((AtherothrombosisAtherothrombosis))
•• AvaproAvapro / / AvalideAvalide(Hypertension)(Hypertension)
•• Abilify Abilify (Psychiatric Disorders)(Psychiatric Disorders)
•• Baraclude Baraclude (Hepatitis B)(Hepatitis B)
•• Reyataz Reyataz (HIV/AIDS)(HIV/AIDS)
•• SustivaSustiva / ATRIPLA / ATRIPLA (HIV/AIDS)(HIV/AIDS)
Exploratory Development•• Androgen Receptor AntagonistsAndrogen Receptor Antagonists (Cancer)(Cancer)•• IGFIGF--1R Antagonist 1R Antagonist (Cancer)(Cancer)•• VEGF RVEGF R--2 Inhibitor 2 Inhibitor (Cancer)(Cancer)•• BrivanibBrivanib--VEGFR/FGFR Inhibitor VEGFR/FGFR Inhibitor (Cancer)(Cancer)•• ErbBErbB/VEGF Receptor Inhibitor /VEGF Receptor Inhibitor (Cancer)(Cancer)•• AntiAnti--CD137 Antibody CD137 Antibody (Cancer)(Cancer)•• EpothiloneEpothilone--FolateFolate (Cancer)(Cancer)•• Met Met KinaseKinase InhibitorInhibitor (Cancer) (Cancer) •• SMO InhibitorSMO Inhibitor (Cancer)(Cancer)•• Hsp90 InhibitorHsp90 Inhibitor (Cancer)(Cancer)•• p38 Kinase Inhibitorsp38 Kinase Inhibitors (Rheumatoid Arthritis)(Rheumatoid Arthritis)•• CCR2/CCR5 Dual AntagonistCCR2/CCR5 Dual Antagonist (Immunology)(Immunology)•• CCR2 Antagonist CCR2 Antagonist (CV / Met)(CV / Met)•• 1111ββHSD InhibitorHSD Inhibitor (Diabetes)(Diabetes)•• DPP4 Inhibitor BackupDPP4 Inhibitor Backup (Diabetes)(Diabetes)•• CB1 Antagonist CB1 Antagonist (Obesity)(Obesity)•• DGAT Inhibitors DGAT Inhibitors (CV / Met)(CV / Met)•• LXR Agonist LXR Agonist (Atherosclerosis)(Atherosclerosis)•• CRF Antagonists CRF Antagonists (Affective Disorders)(Affective Disorders)•• Triple Reuptake InhibitorTriple Reuptake Inhibitor (Depression)(Depression)•• Gamma Gamma SecretaseSecretase InhibitorInhibitor (Alzheimer(Alzheimer’’s) s) •• HCV Inhibitor Target 1 HCV Inhibitor Target 1 (Hepatitis C)(Hepatitis C)•• HCV InhibitorHCV Inhibitor Target 2 Target 2 (Hepatitis C)(Hepatitis C)•• HCV InhibitorHCV Inhibitor Target 3Target 3 (Hepatitis C)(Hepatitis C)•• HIV Attachment Inhibitor HIV Attachment Inhibitor (HIV/AIDS)(HIV/AIDS)•• HIV HIV IntegraseIntegrase Inhibitor Inhibitor (HIV/AIDS)(HIV/AIDS)As of December 2007
7This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development Program Target ProfilesFull Development Program Target Profiles
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in
overweight and obese diabetes patients – driven by the
partnership of Bristol-Myers Squibb and AstraZeneca
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than
current standard of care –driven by the partnership of Bristol-Myers Squibb and
Pfizer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
8This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Current Therapies for Kidney TransplantCurrent Therapies for Kidney Transplant
Significant gains in oneSignificant gains in one--year graft survival rates with year graft survival rates with current therapy current therapy
Less progress on fiveLess progress on five--year patient and graft survivalyear patient and graft survival–– 34% graft loss for deceased donors34% graft loss for deceased donors–– 21% graft loss for living related donors21% graft loss for living related donors
Calcineurin inhibitors (CNIs) are associated withCalcineurin inhibitors (CNIs) are associated withlonglong--term complications term complications
–– Increased risk of chronic allograft nephropathy Increased risk of chronic allograft nephropathy leading to graft loss leading to graft loss
–– Increased risk factors for cardiovascular diseaseIncreased risk factors for cardiovascular disease–– Increased risk of diabetesIncreased risk of diabetes
9This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Belatacept Showed Comparable Efficacy and Belatacept Showed Comparable Efficacy and Improved Safety Over Cyclosporine at 1 YearImproved Safety Over Cyclosporine at 1 YearImmunosuppressive Efficacy Immunosuppressive Efficacy
Low rates of acute rejection, comparable across armsLow rates of acute rejection, comparable across armsComparable patient and graft survivalComparable patient and graft survival
Safety ProfileSafety ProfileLow rates of serious infections and malignancies, Low rates of serious infections and malignancies, comparable across armscomparable across arms
Addressing Key Areas of Unmet NeedAddressing Key Areas of Unmet NeedProtection of renal function Protection of renal function Lower rates of chronic allograft nephropathyLower rates of chronic allograft nephropathyFavorable trends in CV and metabolic parametersFavorable trends in CV and metabolic parameters
Phase II Study IM103-100, 12 month results, NEJM, 353:770, August 25, 2005Phase II Study IM103Phase II Study IM103--100, 12 month results, NEJM, 353:770, August 25, 2005100, 12 month results, NEJM, 353:770, August 25, 2005
10This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Cal
cula
ted
GFR
(Glo
mer
ular
Filt
ratio
n R
ate)
C
alcu
late
d G
FR (G
lom
erul
ar F
iltra
tion
Rat
e)
(ml/m
in/1
.73m
(ml/m
in/1
.73m
22 ))
Months After TransplantMonths After Transplant
Belatacept Showed Stable Kidney Belatacept Showed Stable Kidney Function Over Four YearsFunction Over Four Years
1212 1818 2424 3030 3636 4242 4848
Belatacept (N = 102) Belatacept (N = 102) Cyclosporine (N = 26)Cyclosporine (N = 26)
9090
8080
7070
6060
Oral Presentations: 2007 ATC, San Francisco; 2007 ESOT, Prague Oral Presentations: 2007 ATC, San Francisco; 2007 ESOT, Prague
11This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Belatacept: Initial Registrational Program Belatacept: Initial Registrational Program in Renal Transplantin Renal Transplant
Planning for BLA submission in 1H 09Planning for BLA submission in 1H 09
StudyStudy Study DesignStudy Design EndpointsEndpoints NN
BroadBroad--criteria criteria donordonor
belatacept vs. belatacept vs. cyclosporinecyclosporine
belatacept vs. belatacept vs. cyclosporinecyclosporine
660660
ExtendedExtended--criteria donorcriteria donor
540540
••Death/Graft LossDeath/Graft Loss••Renal function (GFR)Renal function (GFR)••Acute rejectionAcute rejection••Chronic allograft Chronic allograft nephropathynephropathy
12This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development Program Target ProfilesFull Development Program Target Profiles
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in
overweight and obese diabetes patients – driven by the
partnership of Bristol-Myers Squibb and AstraZeneca
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than
current standard of care –driven by the partnership of Bristol-Myers Squibb and
Pfizer
13This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Saxagliptin: DPP4 Inhibition Saxagliptin: DPP4 Inhibition –– An Emerging An Emerging Mechanism for Diabetes TreatmentMechanism for Diabetes Treatment
Once a day, oral route of administrationOnce a day, oral route of administrationWeight neutral and low incidence of hypoglycemiaWeight neutral and low incidence of hypoglycemiaIn clinical trials, safety profile comparable to In clinical trials, safety profile comparable to placeboplaceboProlonged glycemic control at low dose due to:Prolonged glycemic control at low dose due to:
–– Highly potent inhibition of DPP4Highly potent inhibition of DPP4–– Sustained binding to DPP4 active siteSustained binding to DPP4 active site
FixedFixed--dose combinations facilitated by:dose combinations facilitated by:–– Unique formulationUnique formulation–– Efficacy at low doseEfficacy at low dose
14This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Saxagliptin + Metformin Show Improved Saxagliptin + Metformin Show Improved HbAHbA1c1c Reductions at Week 24Reductions at Week 24
* p<0.0001* p<0.0001Bars indicate 95% twoBars indicate 95% two--sided confidence intervalsided confidence intervalPhase III Study Phase III Study --014, ADA, June 2007014, ADA, June 2007
Adjusted Change From BaselineDifference in Adjusted Change from Baseline vs Placebo + Metformin
% C
hang
e in
HbA
% C
hang
e in
HbA
1c1c
PBOPBO+ MET + MET
(N = 175)(N = 175)
SAXA 2.5mgSAXA 2.5mg+ MET+ MET
(N = 186)(N = 186)
SAXA 5mgSAXA 5mg+ MET + MET
(N = 186)(N = 186)
SAXA 10mgSAXA 10mg+ MET+ MET
(N = 180)(N = 180)
*-1
* *-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
--0.730.73 --0.720.72--0.830.83
15This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Saxagliptin Registrational ProgramSaxagliptin Registrational Program
NDA submission targeted for midNDA submission targeted for mid--20082008Target indicationsTarget indications
–– MonotherapyMonotherapy–– AddAdd--on combination therapy on combination therapy
(metformin, TZD, sulfonylurea)(metformin, TZD, sulfonylurea)–– Initial combination therapy with Initial combination therapy with
metforminmetforminPhase III data presentationsPhase III data presentations
–– ADA, June 2008ADA, June 2008–– EASD, Sept 2008EASD, Sept 2008
16This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development Program Target ProfilesFull Development Program Target Profiles
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in
overweight and obese diabetes patients – driven by the
partnership of Bristol-Myers Squibb and AstraZeneca
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than
current standard of care –driven by the partnership of Bristol-Myers Squibb and
Pfizer
17This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
DapagliflozinDapagliflozin: Unique Insulin : Unique Insulin Independent Mechanism of ActionIndependent Mechanism of Action
Indirect Glucose ManagementIndirect Glucose Management
Insulin ActionTZDs
Metformin
Insulin ReleaseSulfonylureas
GLP-1 analoguesDPP4 inhibitors
Enhanced glucose utilization,Increased storage
Direct Glucose ManagementDirect Glucose Management
Insulin-independentglucose reabsorption
inhibitionSGLT2
Glucose elimination / caloric loss
1.1. Complementary to any other Complementary to any other mechanisms to treat diabetesmechanisms to treat diabetes
2.2. Directly reduces hyperglycemiaDirectly reduces hyperglycemia3.3. Promotes calorie loss through Promotes calorie loss through
glucosuriaglucosuria
• ß-cells• Pancreas
• Muscle• Fat cells• Liver
• Kidney
18This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
DapagliflozinDapagliflozin Demonstrated Efficacy in Demonstrated Efficacy in Reducing Fasting Serum GlucoseReducing Fasting Serum Glucose
Cha
nge
in S
erum
Glu
cose
(mg/
dl)
Cha
nge
in S
erum
Glu
cose
(mg/
dl)
from
Day
fr
om D
ay -- 2
(%)
2 (%
)
N = 47N = 47**pp<0.05<0.05†† pp<0.001<0.001
Phase Phase IIaIIa study, ADA, June 2007study, ADA, June 2007
** ††**
††
-9.3 -9.8
3.11.31.3
-6.3
-14.5-17.3
-21.9
--3535
--3030
--2525
--2020
--1515
--1010
--55
00
55
1010
1515Day 2Day 2Day 13Day 13
Dapagliflozin doseDapagliflozin dosePlacebo Placebo 5 mg5 mg 25 mg25 mg 100 mg100 mg
19This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
DapagliflozinDapagliflozin: Increased Urinary Glucose : Increased Urinary Glucose Excretion Leading to Increased Calorie LossExcretion Leading to Increased Calorie Loss
Phase Phase IIaIIa study, ADA, June 2007study, ADA, June 2007
Mea
n (S
D) C
umul
ativ
eM
ean
(SD
) Cum
ulat
ive
urin
ary
gluc
ose
(g/d
ay)
urin
ary
gluc
ose
(g/d
ay)
Dapagliflozin doseDapagliflozin dose
2g/2g/dayday
2g/2g/dayday
4g/4g/dayday2g/2g/
dayday1 g/1 g/dayday
35g/day
66g/day
68g/day
00
2020
4040
6060
8080
100100
120120
Placebo Placebo 5 mg5 mg 25 mg25 mg 100 mg100 mg
Day Day --11Day 14Day 14
20This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
DapagliflozinDapagliflozin Registrational ProgramRegistrational Program
Patient PopulationPatient Population Treatment TypesTreatment TypesTreatment NaTreatment Naïïveve MonotherapyMonotherapy vs. vs.
placeboplaceboInitial combination Initial combination with with metforminmetformin
AddAdd--on Therapyon TherapyTreatment Treatment Experienced Experienced (previous failure)(previous failure) Versus placebo:Versus placebo:
•• metforminmetformin•• sulfonylureasulfonylurea•• TZDTZD•• insulininsulin
Active control:Active control:•• sulfonylureasulfonylurea•• others under others under
considerationconsideration
21This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Building Pipelines Within Products: Building Pipelines Within Products: Full Development Program Target ProfilesFull Development Program Target Profiles
A new cytotoxic designed to overcome resistance
IpilimumabEstablishing a new
immunotherapy paradigm for the treatment of cancer
BelataceptNovel co-stimulation blocker
developed to replace cornerstone therapy in solid
organ transplantation
SaxagliptinBringing a new choice
to the management of diabetes – driven by the partnership of
Bristol-Myers Squibband AstraZeneca
DapagliflozinProviding a new insulin-
independent mechanism for improved outcomes in
overweight and obese diabetes patients – driven by the
partnership of Bristol-Myers Squibb and AstraZeneca
ApixabanPredictable and reliable
anticoagulant with a wider therapeutic window than
current standard of care –driven by the partnership of Bristol-Myers Squibb and
Pfizer
22This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
PropertiesProperties BenefitsBenefits
Orally active Ease of administration
Rapid onset of action Obviates need for overlap with a parenteral anticoagulant
No significant food or drug interactions Simplified dosing
Predictable anticoagulant effect
No routine coagulation monitoring
Renal and extra-renal clearance
Safe in patients with renal insufficiency
Rapid offset of actionSimplifies management in case of bleed or need for intervention
Optimal benefit/risk profile Treatment benefit outweighs risk
Apixaban target profile
Properties of an Ideal AnticoagulantProperties of an Ideal Anticoagulant
23This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
(mg)(mg)
0
5
10
15
20
25
30
35
40
Daily Dose: 5 10 20 Daily Dose: 5 10 20 5 10 20 5 10 20 QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID QD BID Enox WarfEnox Warf Enox WarfEnox Warf
% o
f Pat
ient
s%
of P
atie
nts
Phase II VTE Prevention Study: APROPOS (CV185010), ASH December Phase II VTE Prevention Study: APROPOS (CV185010), ASH December 20062006
Apixaban Demonstrated Greater Efficacy in Preventing Apixaban Demonstrated Greater Efficacy in Preventing VTE / Death Than Standard of Care (Phase II Study)VTE / Death Than Standard of Care (Phase II Study)
ApixabanApixaban ApixabanApixabanBID dosing consistently produced lower rates of VTE/death BID dosing consistently produced lower rates of VTE/death compared with QD dosing with comparable bleeding ratescompared with QD dosing with comparable bleeding rates
VenousVenousThromboembolism (VTE) / Thromboembolism (VTE) /
DeathDeathTotal BleedingTotal Bleeding
24This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
Indication Indication PhasePhase Trial NTrial NVTE prevention (knee replacement)VTE prevention (knee replacement) IIIIII ADVANCEADVANCE--11 3,0003,000
VTE prevention (knee replacement)VTE prevention (knee replacement) IIIIII ADVANCEADVANCE--22 3,0003,000
VTE prevention (hip replacement)VTE prevention (hip replacement) IIIIII ADVANCEADVANCE--3 3 4,0004,000
VTE prevention (medical) VTE prevention (medical) IIIIII ADOPT ADOPT 6,5006,500
Stroke prevention in AF (vs. warfarin)Stroke prevention in AF (vs. warfarin) IIIIII ARISTOTLEARISTOTLE 15,00015,000
Stroke prevention in AF (vs. aspirin)Stroke prevention in AF (vs. aspirin) IIIIII AVERROESAVERROES 5,6005,600
VTE treatment VTE treatment IIIIII To start 2Q 08To start 2Q 08
Acute Coronary Syndrome Acute Coronary Syndrome IIII APPRAISEAPPRAISE--11 1,7001,700
VTE prevention in cancer VTE prevention in cancer IIII Pilot Trial Pilot Trial 160160
Apixaban Clinical Development:Apixaban Clinical Development:Pursuing Multiple Indications SimultaneouslyPursuing Multiple Indications Simultaneously
VTE VTE –– venous thromboembolismvenous thromboembolism
25This presentation is intended solely for an investment communityThis presentation is intended solely for an investment community/industry audience/industry audience--not for promotional use not for promotional use
2008 Key Data Flow2008 Key Data Flow
OrenciaOrenciaLupus: ACR, Oct 2008Lupus: ACR, Oct 2008Early RA: ACR, Oct 2008Early RA: ACR, Oct 2008RA Prevention: EULAR, June 2008RA Prevention: EULAR, June 2008
SprycelSprycel Prostate cancer: ASCO, June 2008Prostate cancer: ASCO, June 2008ErbituxErbitux Lung cancer: ASCO, June 2008Lung cancer: ASCO, June 2008
IxempraIxempra MBC MBC --046 survival data: ASCO Breast, Sept 2008046 survival data: ASCO Breast, Sept 2008MBC MBC --048 survival data: SABCS, Dec 2008048 survival data: SABCS, Dec 2008
BelataceptBelatacept Ph III data available: 4Q 2008Ph III data available: 4Q 2008IpilimumabIpilimumab Metastatic melanoma: ASCO, June 2008Metastatic melanoma: ASCO, June 2008
SaxagliptinSaxagliptin Ph III data: ADA, June 2008Ph III data: ADA, June 2008Ph III data: EASD, Sept 2008Ph III data: EASD, Sept 2008
DapagliflozinDapagliflozin Ph IIb data: ADA, June 2008Ph IIb data: ADA, June 2008
PlavixPlavix ACTIVEACTIVE--A data available: 2H 2008A data available: 2H 2008CURRENT data available: 2H 2008CURRENT data available: 2H 2008
ApixabanApixaban Ph II ACS data: ESC, Aug/Sept 2008Ph II ACS data: ESC, Aug/Sept 2008Ph III VTE prevention data: ASH, Dec 2008Ph III VTE prevention data: ASH, Dec 2008
top related